Temat: "Leukemia, Lymphocytic, Chronic, B-Cell" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
Autorzy:: Mouhssine S; Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, 28100 Novara, Italy.
Maher N; Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, 28100 Novara, Italy.
Matti BF; Department of Hematology and Bone Marrow Transplant, Hematology and Bone Marrow Transplant Center, Medical City, Baghdad 00964, Iraq.
Alwan AF; Department of Hematology and Bone Marrow Transplant, Hematology and Bone Marrow Transplant Center, Medical City, Baghdad 00964, Iraq.; Department of Clinical Hematology, The National Center of Hematology, Mustansiriyah University, Baghdad 10015, Iraq.
Gaidano G; Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, 28100 Novara, Italy.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Mar 12; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 12.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Humans ; Adult ; Agammaglobulinaemia Tyrosine Kinase ; Ligands ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia.
Autorzy:: Kaya A; University of Health Sciences Türkiye, Van Training and Research Hospital, Clinic of Hematology, Van, Türkiye.
Aras İ; Van Yüzüncü Yıl University Faculty of Medicine, Department of Medical Pathology, Van, Türkiye.
Özkan Kurtgöz P; University of Health Sciences Türkiye, Van Training and Research Hospital, Clinic of Nephrology, Van, Türkiye.
Çakıroğlu U; Van Yüzüncü Yıl University Faculty of Medicine, Department of Medical Oncology, Van, Türkiye.; Pokaż więcej
Źródło:: Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Mar 01; Vol. 41 (1), pp. 57-58.
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*/complications
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Vasculitis, Leukocytoclastic, Cutaneous*/chemically induced
Vasculitis, Leukocytoclastic, Cutaneous*/diagnosis
Adenine/*analogs & derivatives
Humans ; Piperidines/adverse effects
SCR Disease Name:: Erythema elevatum diutinum

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Successful Management of Ibrutinib-Induced Thrombocytopenia in a Patient with Chronic Lymphocytic Leukemia: No Interruption, Only Reduction
Autorzy:: Erdem S; İstanbul University, İstanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Türkiye
Nalçacı M; İstanbul University, İstanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Türkiye; Pokaż więcej
Źródło:: Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Mar 01; Vol. 41 (1), pp. 55-56. Date of Electronic Publication: 2023 Dec 22.
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*/complications
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Anemia*
Thrombocytopenia*/chemically induced
Thrombocytopenia*/diagnosis
Thrombocytopenia*/drug therapy
Adenine/*analogs & derivatives
Humans ; Piperidines/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Degradation trumps mutations in cancer.
Autorzy:: Davis RE; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Westin JR; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.; Pokaż więcej
Źródło:: Science (New York, N.Y.) [Science] 2024 Feb 02; Vol. 383 (6682), pp. 480-481. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Resistance, Neoplasm*/drug effects
Drug Resistance, Neoplasm*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Proteolysis*/drug effects
Cell Line, Tumor ; Mutation ; Humans

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Autorzy:: Montoya S; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Bourcier J; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Noviski M; Nurix Therapeutics, San Francisco, CA, USA.
Lu H; Nurix Therapeutics, San Francisco, CA, USA.
Thompson MC; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chirino A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Jahn J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Sondhi AK; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Gajewski S; Nurix Therapeutics, San Francisco, CA, USA.
Tan YSM; Nurix Therapeutics, San Francisco, CA, USA.
Yung S; Nurix Therapeutics, San Francisco, CA, USA.
Urban A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Wang E; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Han C; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Mi X; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kim WJ; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sievers Q; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Auger P; Nurix Therapeutics, San Francisco, CA, USA.
Bousquet H; Nurix Therapeutics, San Francisco, CA, USA.
Brathaban N; Nurix Therapeutics, San Francisco, CA, USA.
Bravo B; Nurix Therapeutics, San Francisco, CA, USA.
Gessner M; Nurix Therapeutics, San Francisco, CA, USA.
Guiducci C; Nurix Therapeutics, San Francisco, CA, USA.
Iuliano JN; Nurix Therapeutics, San Francisco, CA, USA.
Kane T; Nurix Therapeutics, San Francisco, CA, USA.
Mukerji R; Nurix Therapeutics, San Francisco, CA, USA.
Reddy PJ; Nurix Therapeutics, San Francisco, CA, USA.
Powers J; Nurix Therapeutics, San Francisco, CA, USA.
Sanchez Garcia de Los Rios M; Nurix Therapeutics, San Francisco, CA, USA.
Ye J; Nurix Therapeutics, San Francisco, CA, USA.
Barrientos Risso C; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Tsai D; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Pardo G; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Notti RQ; Laboratory of Molecular Electron Microscopy, Rockefeller University, New York, NY, USA.
Pardo A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Affer M; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Nawaratne V; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Totiger TM; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Pena-Velasquez C; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rhodes JM; Division of Hematology-Oncology, Department of Medicine at Zucker School of Medicine at Hofstra/Northwell, CLL Research and Treatment Center, Lake Success, NY, USA.
Zelenetz AD; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alencar A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Roeker LE; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mehta S; Gene Editing and Screening Core Facility, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Institute and Cancer Center, New York, NY, USA.
Garippa R; Gene Editing and Screening Core Facility, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Institute and Cancer Center, New York, NY, USA.
Linley A; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Soni RK; Proteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
Skånland SS; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Brown RJ; Nurix Therapeutics, San Francisco, CA, USA.
Mato AR; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hansen GM; Nurix Therapeutics, San Francisco, CA, USA.
Abdel-Wahab O; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Taylor J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.; Pokaż więcej
Źródło:: Science (New York, N.Y.) [Science] 2024 Feb 02; Vol. 383 (6682), pp. eadi5798. Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:: Journal Article
MeSH Terms:: Agammaglobulinaemia Tyrosine Kinase*/genetics
Agammaglobulinaemia Tyrosine Kinase*/metabolism
Ikaros Transcription Factor*/metabolism
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Proteolysis*/drug effects
Drug Resistance, Neoplasm*/drug effects
Humans ; Mutation ; Phosphorylation ; Signal Transduction

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Analysis of Mutational Status of IGHV , and Cytokine Polymorphisms as Prognostic Factors in Chronic Lymphocytic Leukemia: The Romanian Experience.
Autorzy:: Balla B; Department of Medical Genetics, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania.; Center for Advanced Medical and Pharmaceutical Research, Genetics Laboratory, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania.; Medical Genetics Laboratory, Emergency County Hospital of Targu Mures, 540136 Targu Mures, Romania.
Tripon F; Department of Medical Genetics, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania.; Center for Advanced Medical and Pharmaceutical Research, Genetics Laboratory, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania.; Medical Genetics Laboratory, Emergency County Hospital of Targu Mures, 540136 Targu Mures, Romania.
Lazar E; Department of Internal Medicine, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania.
Bănescu C; Department of Medical Genetics, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania.; Center for Advanced Medical and Pharmaceutical Research, Genetics Laboratory, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania.; Medical Genetics Laboratory, Emergency County Hospital of Targu Mures, 540136 Targu Mures, Romania.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Feb 01; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis
Humans ; Aged ; Immunoglobulin Variable Region/genetics ; Interleukin-10/genetics ; Cytokines/genetics ; Tumor Necrosis Factor-alpha/genetics ; Prognosis ; Romania ; Mutation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells.
Autorzy:: Rouleau M; Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada.; Cancer research center of Université Laval, Québec, Canada.
Villeneuve L; Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada.; Cancer research center of Université Laval, Québec, Canada.
Allain EP; Molecular Genetics Laboratory, Vitalité Health Network, Dr. Georges-L.-Dumont University Hospital Center, Moncton, NB, Canada.
McCabe-Leroux J; Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada.; Cancer research center of Université Laval, Québec, Canada.
Tremblay S; Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada.; Cancer research center of Université Laval, Québec, Canada.
Nguyen Van Long F; Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada.; Cancer research center of Université Laval, Québec, Canada.
Uchil A; Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada.; Cancer research center of Université Laval, Québec, Canada.
Joly-Beauparlant C; Cancer research center of Université Laval, Québec, Canada.; CRCHUQc-UL and Faculty of Medicine, Université Laval, Québec, Québec, Canada.
Droit A; Cancer research center of Université Laval, Québec, Canada.; CRCHUQc-UL and Faculty of Medicine, Université Laval, Québec, Québec, Canada.
Guillemette C; Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada. .; Cancer research center of Université Laval, Québec, Canada. .; Canada Research Chair in Pharmacogenomics, Faculty of Pharmacy, Université Laval, Québec, QC, Canada. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Apr 02; Vol. 24 (1), pp. 410. Date of Electronic Publication: 2024 Apr 02.
Typ publikacji:: Journal Article
MeSH Terms:: NF-kappa B*/metabolism
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Humans ; Prognosis ; Apoptosis ; RNA ; Glucuronosyltransferase/genetics ; Minor Histocompatibility Antigens

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Promoting leisure functions through setting creative linguistic landscapes in recreational zones.
Autorzy:: Sun K; School of Tourism & Culinary, Yangzhou University, Yangzhou, PR China.
Tian X; School of Tourism & Culinary, Yangzhou University, Yangzhou, PR China.
Xia J; School of Tourism & Culinary, Yangzhou University, Yangzhou, PR China.
Li Q; School of Tourism & Culinary, Yangzhou University, Yangzhou, PR China.
Hou B; School of Tourism & Culinary, Yangzhou University, Yangzhou, PR China.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Mar 22; Vol. 19 (3), pp. e0299775. Date of Electronic Publication: 2024 Mar 22 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*
Humans ; Leisure Activities/psychology ; Creativity ; Cognition ; Linguistics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Persistence of Chronic Lymphocytic Leukemia Stem-like Populations under Simultaneous In Vitro Treatment with Curcumin, Fludarabine, and Ibrutinib: Implications for Therapy Resistance.
Autorzy:: Bistué-Rovira À; Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona (UAB), 08193 Cerdanyola del Vallès, Spain.
Rico LG; Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona (UAB), 08916 Badalona, Spain.
Bardina J; Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Juncà J; MDS Group, Institut de Recerca Contra la Leucèmia Josep Carreras, 08916 Badalona, Spain.
Granada I; MDS Group, Institut de Recerca Contra la Leucèmia Josep Carreras, 08916 Badalona, Spain.
Bradford JA; Thermo Fisher Scientific, Fort Collins, CO 80524, USA.
Ward MD; Thermo Fisher Scientific, Fort Collins, CO 80524, USA.
Salvia R; Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona (UAB), 08916 Badalona, Spain.
Solé F; MDS Group, Institut de Recerca Contra la Leucèmia Josep Carreras, 08916 Badalona, Spain.
Petriz J; Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona (UAB), 08916 Badalona, Spain.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Feb 07; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*/metabolism
Curcumin*/pharmacology
Curcumin*/therapeutic use
Piperidines*
Adenine/*analogs & derivatives
Vidarabine/*analogs & derivatives
Humans ; Tetraploidy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: 40 years of adding more fructose to high fructose corn syrup than is safe, through the lens of malabsorption and altered gut health-gateways to chronic disease.
Autorzy:: DeChristopher LR; East Fishkill, USA. .; Pokaż więcej
Źródło:: Nutrition journal [Nutr J] 2024 Feb 02; Vol. 23 (1), pp. 16. Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:: Journal Article
MeSH Terms:: High Fructose Corn Syrup*/adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell*
Malus*
Asthma*/epidemiology
Adult ; Humans ; Child ; Fructose/adverse effects ; Dysbiosis ; Glucose ; Chronic Disease ; Sucrose

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Innovation of the protocol for the application of cryolipolysis: Effects and mechanisms of action.
Autorzy:: Palauro CRT; Centro Universitário de Vila Velha, Vila Velha, Brazil.
Meyer PF; International Research Group, Natal, Brazil.
Soares CD; International Research Group, Natal, Brazil.
de Morais Carreiro E; International Research Group, Natal, Brazil.
de Paiva Dumaresq F; Universidade Estadual de Ciências da Saúde de Alagoas, Maceio, Brazil.
de Oliveira FCC; Universidade Federal do Rio Grande do Norte, Natal, Brazil.
de Andrade ALM; Universidade Brasil, Sao Paulo, Brazil.
da S P S Daumas P; Universidade Estácio de Sá, Rio de Janeiro, Brazil.; Pokaż więcej
Źródło:: Journal of cosmetic dermatology [J Cosmet Dermatol] 2024 Feb; Vol. 23 (2), pp. 441-449. Date of Electronic Publication: 2023 Nov 20.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Cryosurgery*/adverse effects
Cryosurgery*/methods
Leukemia, Lymphocytic, Chronic, B-Cell*/surgery
Lipectomy*/methods
Humans ; Caspase 3 ; Subcutaneous Fat/surgery

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.
Autorzy:: Zygmunciak P; Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
Robak T; Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland.; Department of General Hematology, Copernicus Memorial Hospital, 93-510 Lodz, Poland.
Puła B; Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Jan 27; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 27.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Lymphoma, B-Cell*/drug therapy
Humans ; Protein-Tyrosine Kinases ; Agammaglobulinaemia Tyrosine Kinase ; Protein Kinase Inhibitors/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Expression Pattern and Prognostic Significance of the Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Chronic Lymphocytic Leukemia.
Autorzy:: Tomic Vujovic K; Clinic for Hematology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Ugrin M; Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Tosic N; Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Vukovic V; Clinic for Hematology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Marjanovic I; Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Kostic T; Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Stankovic S; Center for Medical Biochemistry, University Clinical Center of Serbia, 11000 Belgrade, Serbia.; Department of Biochemistry, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Otasevic V; Clinic for Hematology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Sarac S; Clinic for Hematology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Antic D; Clinic for Hematology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.; School of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Pavlovic S; Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Karan-Djurasevic T; Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Jan 11; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
RNA, Long Noncoding*/genetics
Hematologic Neoplasms*
Humans ; Prognosis ; Leukocytes, Mononuclear

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: CAD204520 Targets NOTCH1 PEST Domain Mutations in Lymphoproliferative Disorders.
Autorzy:: Pagliaro L; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.; Translational Hematology and Chemogenomics (THEC), University of Parma, 43126 Parma, Italy.; Hematology and BMT Unit, University Hospital of Parma, 43126 Parma, Italy.
Cerretani E; Translational Hematology and Chemogenomics (THEC), University of Parma, 43126 Parma, Italy.; Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.
Vento F; Translational Hematology and Chemogenomics (THEC), University of Parma, 43126 Parma, Italy.; Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.
Montanaro A; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.; Translational Hematology and Chemogenomics (THEC), University of Parma, 43126 Parma, Italy.
Moron Dalla Tor L; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.; Translational Hematology and Chemogenomics (THEC), University of Parma, 43126 Parma, Italy.
Simoncini E; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.; Translational Hematology and Chemogenomics (THEC), University of Parma, 43126 Parma, Italy.
Giaimo M; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.; Translational Hematology and Chemogenomics (THEC), University of Parma, 43126 Parma, Italy.; Hematology and BMT Unit, University Hospital of Parma, 43126 Parma, Italy.
Gherli A; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.; Translational Hematology and Chemogenomics (THEC), University of Parma, 43126 Parma, Italy.; Hematology and BMT Unit, University Hospital of Parma, 43126 Parma, Italy.
Zamponi R; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.; Translational Hematology and Chemogenomics (THEC), University of Parma, 43126 Parma, Italy.; Hematology and BMT Unit, University Hospital of Parma, 43126 Parma, Italy.
Tartaglione I; Translational Hematology and Chemogenomics (THEC), University of Parma, 43126 Parma, Italy.
Lorusso B; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
Scita M; Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.
Russo F; Hematology and BMT Unit, University Hospital of Parma, 43126 Parma, Italy.
Sammarelli G; Hematology and BMT Unit, University Hospital of Parma, 43126 Parma, Italy.
Todaro G; Hematology and BMT Unit, University Hospital of Parma, 43126 Parma, Italy.
Silini EM; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
Rigolin GM; Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.; Hematology Unit, University Hospital of Ferrara, 44121 Ferrara, Italy.
Quaini F; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
Cuneo A; Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy.; Hematology Unit, University Hospital of Ferrara, 44121 Ferrara, Italy.
Roti G; Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.; Translational Hematology and Chemogenomics (THEC), University of Parma, 43126 Parma, Italy.; Hematology and BMT Unit, University Hospital of Parma, 43126 Parma, Italy.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Jan 07; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 07.
Typ publikacji:: Journal Article
MeSH Terms:: Hematologic Neoplasms*
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Lymphoproliferative Disorders*/drug therapy
Lymphoproliferative Disorders*/genetics
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma*
Humans ; Mutation ; Receptor, Notch1/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with Reed-Sternberg-like cells with no convincing evidence of classic Hodgkin lymphoma.
Autorzy:: Abraham LK; Department of Pathology, Rajagiri Hospital Aluva, Ernakulam, Kerala, India.
Paul M; Department of Clinical Hematology and Hemato-Oncology, Rajagiri Hospital Aluva, Ernakulam, Kerala, India.; Pokaż więcej
Źródło:: Indian journal of pathology & microbiology [Indian J Pathol Microbiol] 2024 Jan-Mar; Vol. 67 (1), pp. 151-152.
Typ publikacji:: Journal Article
MeSH Terms:: Hodgkin Disease*/diagnosis
Hodgkin Disease*/pathology
Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Lymphoma, B-Cell*
Humans ; Lymphocytes

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia.
Autorzy:: Huntington SF; Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, Connecticut, USA.
de Nigris E; MSD (UK) Limited, London, UK.
Puckett JT; COVIA Health Solutions, Ambler, Pennsylvania, USA.
Kamal-Bahl S; COVIA Health Solutions, Ambler, Pennsylvania, USA.
Farooqui M; Merck & Co., Inc, Rahway, New Jersey, USA.
Ryland K; Merck & Co., Inc, Rahway, New Jersey, USA.
Sarpong EM; Merck & Co., Inc, Rahway, New Jersey, USA.
Leng S; Merck & Co., Inc, Rahway, New Jersey, USA.
Yang X; Merck & Co., Inc, Rahway, New Jersey, USA.
Doshi JA; Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2024 Jan; Vol. 13 (2), pp. e6953.
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/epidemiology
Adenine/*analogs & derivatives
Humans ; Aged ; United States/epidemiology ; Medicare ; Adenine/adverse effects ; Piperidines/adverse effects ; Protein Kinase Inhibitors/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Synthesis and Pro-Apoptotic Effects of Nitrovinylanthracenes and Related Compounds in Chronic Lymphocytic Leukaemia (CLL) and Burkitt's Lymphoma (BL).
Autorzy:: Byrne AJ; School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland.
Bright SA; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland.
McKeown JP; School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland.
Bergin A; School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland.
Twamley B; School of Chemistry, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland.
McElligott AM; Discipline of Haematology, School of Medicine, Trinity Translational Medicine Institute, St. James's Hospital and Trinity College, Dublin 8, D08 W9RT Dublin, Ireland.
Noorani S; School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland.
Kandwal S; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland.
Fayne D; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland.
O'Boyle NM; School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland.
Williams DC; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland.
Meegan MJ; School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2023 Dec 14; Vol. 28 (24). Date of Electronic Publication: 2023 Dec 14.
Typ publikacji:: Journal Article
MeSH Terms:: Burkitt Lymphoma*/drug therapy
Burkitt Lymphoma*/metabolism
Burkitt Lymphoma*/pathology
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Humans ; B-Lymphocytes/metabolism ; Cell Line ; Anthracenes

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study.
Autorzy:: Hong Y; Department of Pharmacy, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital), Wuxi, Jiangsu, China.
Chen X; Department of Pharmacy, Wuxi Ninth People's Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital), Liangxi Road 999, Wuxi, Jiangsu, 214062, China. .
Hong Y; Department of Pharmacy, Wuxi Ninth People's Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital), Liangxi Road 999, Wuxi, Jiangsu, 214062, China.
Xiao X; Department of Pharmacy, Wuxi Ninth People's Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital), Liangxi Road 999, Wuxi, Jiangsu, 214062, China.
Wang Y; Department of Pharmacy, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital), Wuxi, Jiangsu, China.
You X; Department of Pharmacy, Wuxi Ninth People's Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital), Liangxi Road 999, Wuxi, Jiangsu, 214062, China.
Mi J; Department of Sports Medicine, Wuxi Ninth People's Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital), Wuxi, Jiangsu, China.
Zhou T; Department of Pharmacy, Wuxi Ninth People's Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital), Liangxi Road 999, Wuxi, Jiangsu, 214062, China.
Zheng P; Department of Pharmacy, Ningbo No. 6 Hospital, Ningbo, Zhejiang, China.
Huang Z; Department of Oncology, Wuxi Ninth People's Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital), Wuxi, Jiangsu, China.; Pokaż więcej
Źródło:: BMC health services research [BMC Health Serv Res] 2023 Dec 05; Vol. 23 (1), pp. 1355. Date of Electronic Publication: 2023 Dec 05.
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bendamustine Hydrochloride/therapeutic use ; Cost-Benefit Analysis ; Mutation ; Rituximab/therapeutic use ; Tumor Suppressor Protein p53/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Melanoma and CLL co-occurrence and survival: role of KC history.
Autorzy:: Zhao Y; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Amorrortu RP; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Stewart SC; Department of Cancer Registry, Moffitt Cancer Center, Tampa, FL, USA.
Ghia KM; Collaborative Data Services Core, Moffitt Cancer Center, Tampa, FL, USA.
Williams VL; Collaborative Data Services Core, Moffitt Cancer Center, Tampa, FL, USA.
Sondak VK; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Tsai KY; Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA.
Pinilla-Ibarz J; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Chavez JC; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Rollison DE; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2023 Nov 09; Vol. 23 (1), pp. 1084. Date of Electronic Publication: 2023 Nov 09.
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*/complications
Leukemia, Lymphocytic, Chronic, B-Cell*/epidemiology
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Skin Neoplasms*/epidemiology
Melanoma*/complications
Melanoma*/epidemiology
Carcinoma*/pathology
Humans ; Retrospective Studies ; Case-Control Studies ; Keratinocytes/pathology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Acquired von Willebrand's Syndrome in a Patient with Concomitant Chronic Lymphocytic Lymphoma and Smoldering Multiple Myeloma.
Autorzy:: Haribhakti N; Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI.
Lee H; Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI.
Quesenberry M; Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI.
Reagan J; Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI.; Pokaż więcej
Źródło:: Rhode Island medical journal (2013) [R I Med J (2013)] 2024 Jan 04; Vol. 107 (1), pp. 7-11. Date of Electronic Publication: 2024 Jan 04.
Typ publikacji:: Journal Article
MeSH Terms:: Leukemia, Lymphocytic, Chronic, B-Cell*/complications
Smoldering Multiple Myeloma*
von Willebrand Diseases*/complications
von Willebrand Diseases*/diagnosis
Humans ; Female ; von Willebrand Factor ; Hemorrhage

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Leukemia, Lymphocytic, Chronic, B-Cell"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język